De-identified Health Data Market

De-identified Health Data Market Summary

The global de-identified health data market size was estimated at USD 8.80 billion in 2025 and is projected to reach USD 17.93 billion by 2033, growing at a CAGR of 9.37% from 2026 to 2033. The market is driven by the increasing integration of data analytics in healthcare, which supports large-scale studies and predictive modeling without breaching patient confidentiality.

Regulatory frameworks such as GDPR and HIPAA further incentivize using de-identified data for compliance. Advancements in AI and machine learning amplify the need for extensive, privacy-compliant datasets to improve diagnostic and therapeutic methods. In addition, the surge in data from wearable devices, sensors, and electronic health records (EHRs) has expanded the scope for de-identified data in secondary applications.

De-identified health data is essential for clinical research as it allows researchers to analyze large datasets while protecting patient privacy. This data identifies trends, evaluates treatment effectiveness, and supports population health studies without compromising individual identities. By leveraging de-identified data, researchers can enhance the quality of their findings and facilitate advancements in medical knowledge and practice.

For instance, in April 2023, Philips and the MIT Institute for Medical Engineering and Science (IMES) collaborated to develop an enhanced critical care dataset to advance clinical research and AI applications in healthcare. This dataset includes de-identified data from ICU patients and integrates comprehensive clinical information to support researchers and educators in gaining insights into critical care and improving patient outcomes. The initiative fosters innovation in AI-driven healthcare solutions, contributing to more accurate diagnostics and personalized treatments.

Furthermore, de-identification facilitates collaboration and innovation within the healthcare sector by enabling secure patient data sharing across various healthcare systems, thereby advancing diagnostic and treatment technologies. Moreover, it provides critical data necessary for training AI systems, enhancing the accuracy and relevance of medical imaging for disease detection and analysis. This approach protects patient privacy and drives improvements in healthcare outcomes.

For instance, in December 2023, nference, Inc., a software company focused on transforming healthcare data for research, partnered with Emory Healthcare, Georgia's largest academic health system, to enhance access to diverse, aggregated, de-identified data. This initiative aims to accelerate research efforts, improve disease diagnosis, and facilitate the development of new treatments. The collaboration reflects a mutual commitment to advancing medical knowledge, promoting innovation, and enhancing the health and well-being of individuals and communities globally.

“This collaboration with nference allows us to join a federated data network of leading institutions that will enable ground-breaking research. Together, we can work to improve lives and provide hope, tackling some of the most critical health care challenges of our time while delivering comprehensive, data-driven insights.”

- Joe Depa, chief data and analytics officer at Emory Healthcare and Emory University

Global De-identified Health Data Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 - 2033. For this report, Grand View Research has segmented the global de-identified health data market report based on type of data, application, end use, and region:

• Type of Data Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical Data
• Genomic Data
• Patient Demographics
• Prescription Data
• Claims Data
• Behavioral Data
• Wearable and Sensor Data
• Survey and Patient-Reported Data
• Imaging Data
• Laboratory Data
• Hospital and Provider Data
• Social Determinants of Health (SDoH) Data
• Pharmacogenomic Data
• Biometric Data
• Operational and Financial Data
• Epidemiological Data
• Healthcare Utilization Data
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical Research and Trials
• Public Health
• Precision Medicine
• Health Economics and Outcomes Research (HEOR)
• Population Health Management
• Drug Discovery and Development
• Healthcare Quality Improvement
• Insurance Underwriting and Risk Assessment
• Market Access and Commercial Strategy
• Business Intelligence and Operational Efficiency
• Telemedicine and Remote Monitoring
• Patient Engagement and Support Programs
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical Companies
• Biotechnology Firms
• Medical Device Manufacturers
• Healthcare Providers
• Insurance Companies/ Healthcare Payers
• Research Institutions
• Government Agencies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more